Calliditas pushing on with kidney disease drug after IPO successCalliditas Therapeutics has just pulled off the largest biotech IPO in Europe this year and is using it Share XCalliditas pushing on with kidney disease drug after IPO successhttps://pharmaphorum.com/r-d/views-analysis-r-d/calliditas-pushing-kidney-disease-drug-ipo-success/
Otsuka has high hopes for its ‘drug creation engine’ acquisitionOtsuka is paying $430 million for a US clinical-stage biotech company it hopes will act as a ‘drug Share XOtsuka has high hopes for its ‘drug creation engine’ acquisitionhttps://pharmaphorum.com/news/otsuka-biotech-visterra-hierotope/
